Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 10/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ESRRA | P11474 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | F7 | P08709 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7039435 | 0.92 | CYP19A1 (0.51) | CYP19A1ADRB3TRPV1NPC1AR | |
| SCHEMBL8604748 | 0.92 | CYP19A1 (0.51) | CYP19A1ADRB3TRPV1NPC1AR | |
| SCHEMBL8607536 | 0.89 | CYP19A1 (0.52) | CYP19A1ADRB3TRPV1NPC1AR | |
| SCHEMBL6074483 | 0.85 | ADRB3 (0.59) | CYP19A1ADRB3ADRB2 | |
| SCHEMBL7669045 | 0.85 | CYP19A1 (0.47) | CYP19A1ADRB3TRPV1NPC1AR | |
| SCHEMBL6328526 | 0.84 | ADRB3 (0.46) | CYP19A1ADRB3ADRB2ADRB1 | |
| SCHEMBL2456888 | 0.83 | ADRB3 (0.53) | CYP19A1ADRB3ADRB2 | |
| SCHEMBL6074905 | 0.83 | ADRB3 (0.53) | CYP19A1ADRB3ADRB2 | |
| SCHEMBL7119142 | 0.83 | ADRB3 (0.53) | CYP19A1ADRB3ADRB2 | |
| SCHEMBL5479847 | 0.83 | ADRB3 (0.53) | CYP19A1ADRB3ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148427-B2 | Benzylamine derivative or pharmaceutically acceptable acid addition salt thereof, and use thereof for medical purposes | TORAY INDUSTRIES, INC. (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20100099769-A1 | BENZYLAMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF, AND USE THEREOF FOR MEDICAL PURPOSES | TORAY INDUSTRIES, INC. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-7417169-B2 | Amino alcohol derivatives, medicinal composition containing the same, and use of these | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-08-26 | — | — | US | disclosed |
| US-20070078184-A1 | Amino alcohol derivatives, medicinal composition containing the same, and use of these | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-04-05 | — | — | US | disclosed |
| EP-1679304-A1 | AMINO ALCOHOL DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USE OF THESE | Kissei Pharmaceutical Co., Ltd. (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078184-A1 | Amino alcohol derivatives, medicinal composition containing the same, and use of these | ADRB2, ADRA2A, ADRA1A | CYP19A1 578/4885ADRB3 5/4885TRPV1 1104/4885 |
| US-20100099769-A1 | BENZYLAMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF, AND USE THEREOF FOR MEDICAL PURPOSES | UROD, BCAT2, AADAT | CYP19A1 978/4885ADRB3 647/4885TRPV1 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.